


**Getting better Outcomes with Chimeric Antigen Receptor T-cell therapy  
 (GO-CART): A BioCanRx Research Excelsator to Safely and Effectively  
 Translate CAR T-Cell Therapy for Hematological Malignancies**

Jan. 17, 2017 to Dec. 31, 2019

**Highlights**

- A unique world-class translational research platform
- Creates a clinical trial protocol that is better than any previously designed cellular therapy trial in the CAR T arena using stakeholder engagement throughout the process



**About the project**

The vast majority of early phase clinical trials fail due to feasibility (e.g. patient recruitment), safety, or efficacy concerns. Although only a small number of clinical trials of CAR T cells have been done, potential issues with safety, efficacy, and economic viability have already been identified. To avoid these pitfalls, the GO-CART Excelsator program will help BioCanRx scientist effectively use CAR T cells in Canada, a new treatment process for blood cancers.

This project team, led by Dr. Lalu, will address these concerns to formulate a trial protocol that will be feasible, safe, effective, and economical. Experts drawn from different disciplines are coming together to create a “team-science” approach. First, they will perform comprehensive reviews of existing pre-clinical and clinical studies of CAR T cells to help them understand how beneficial CAR T cells may be and identify gaps in their knowledge. Then, they will perform knowledge translation stakeholder engagement studies with patients and clinicians to identify values/preferences for an early

phase clinical trial of CAR T cells. They will go on to perform an economic evaluation to ensure they develop a therapy that is feasible for our health-care system. Finally, they will conduct studies of eligible patients to make sure that the criteria to enter their planned trial will allow enough patients to participate.

The multi-disciplinary team believes this pilot project will provide a template for future therapeutics to be evaluated and trials to be designed in an evidence-informed manner. This will accelerate safe and effective bench-to-bedside translation while providing a documented and transparent process. By addressing issues that most first-in-human/early phase trials encounter, this platform will offer a structured method to evaluate available data and design an evidence informed trial protocol for CAR T-cell therapy of hematologic malignancies.



# Project Investigators



## Partners

BC Cancer Agency

Health Canada

University of Manitoba

Canadian Blood and Marrow Transplant  
Group – University of Calgary

Leukemia & Lymphoma Society of  
Canada

Ottawa Methods Centre

## Key Outputs

Integrated Knowledge Translation

Preclinical and Clinical Systematic  
Reviews

Knowledge Translation (Interviews)

Knowledge Translation (Survey)

Early Economic Evaluation

Retrospective Cohort Study

Prospective Cohort Study

Finalized Evidence Informed Clinical  
Phase I/II Trial Protocol

The power to kill cancer lies within us.  
Let's tell our bodies how.

